Cam Gallagher Sells 12,500 Shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Stock
Cam Gallagher Sells 12,500 Shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Stock
Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL – Get Rating) President Cam Gallagher sold 12,500 shares of the firm's stock in a transaction that occurred on Thursday, September 15th. The shares were sold at an average price of $25.26, for a total transaction of $315,750.00. Following the completion of the sale, the president now owns 454,385 shares of the company's stock, valued at $11,477,765.10. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.
納斯達克(股票代碼:ZNTL-GET)總裁在9月15日星期四的一次交易中出售了12,500股該公司股票。這些股票的平均價格為25.26美元,總成交額為315,750.00美元。出售完成後,總裁現在擁有該公司454,385股股票,價值11,477,765.10美元。這筆交易是在提交給美國證券交易委員會的一份文件中披露的,可以通過以下鏈接訪問該文件。
Zentalis Pharmaceuticals Price Performance
Zentaris藥品價格表現
Shares of Zentalis Pharmaceuticals stock opened at $23.86 on Friday. The firm has a fifty day moving average price of $28.21 and a 200 day moving average price of $30.30. Zentalis Pharmaceuticals, Inc. has a 1 year low of $17.33 and a 1 year high of $87.19. The stock has a market cap of $1.36 billion, a PE ratio of -6.20 and a beta of 1.88.
上週五,Zentalis製藥公司的股票開盤報23.86美元。該公司的50日移動平均價為28.21美元,200日移動平均價為30.30美元。Zentalis PharmPharmticals,Inc.的一年低點為17.33美元,一年高位為87.19美元。該股市值13.6億美元,市盈率為-6.20,貝塔係數為1.88。
Zentalis Pharmaceuticals (NASDAQ:ZNTL – Get Rating) last issued its earnings results on Tuesday, August 9th. The company reported ($1.34) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.21) by ($0.13). As a group, equities analysts expect that Zentalis Pharmaceuticals, Inc. will post -4.78 EPS for the current year.
Zentalis製藥(納斯達克:ZNTL-GET評級)最近一次發佈財報是在8月9日(星期二)。該公司公佈了該季度每股收益(EPS)(1.34美元),低於(1.21美元)和(0.13美元)的普遍預期。作為一個整體,股票分析師預計,Zentalis製藥公司本年度的每股收益將達到4.78美元。
Analyst Ratings Changes
分析師評級發生變化
Institutional Trading of Zentalis Pharmaceuticals
Zentaris製藥的制度性交易
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Federated Hermes Inc. grew its position in Zentalis Pharmaceuticals by 14.1% during the second quarter. Federated Hermes Inc. now owns 1,085,139 shares of the company's stock valued at $30,492,000 after buying an additional 134,206 shares during the period. Amundi acquired a new stake in Zentalis Pharmaceuticals during the second quarter valued at $143,000. Legal & General Group Plc grew its position in Zentalis Pharmaceuticals by 38.1% during the second quarter. Legal & General Group Plc now owns 35,491 shares of the company's stock valued at $998,000 after buying an additional 9,791 shares during the period. Goldman Sachs Group Inc. grew its position in Zentalis Pharmaceuticals by 49.9% during the second quarter. Goldman Sachs Group Inc. now owns 397,570 shares of the company's stock valued at $11,171,000 after buying an additional 132,324 shares during the period. Finally, Woodline Partners LP grew its position in Zentalis Pharmaceuticals by 344.9% during the second quarter. Woodline Partners LP now owns 181,272 shares of the company's stock valued at $5,094,000 after buying an additional 140,524 shares during the period.
幾家對衝基金和其他機構投資者最近增持或減持了該公司的股份。聯合愛馬仕公司在第二季度將其在Zentalis製藥公司的頭寸增加了14.1%。聯合愛馬仕公司目前持有1,085,139股該公司股票,價值30,492,000美元,在此期間又購買了134,206股。Amundi在第二季度收購了Zentalis製藥公司的新股份,價值14.3萬美元。第二季度,Legal&General Group Plc在Zentalis製藥公司的持股增加了38.1%。Legal&General Group Plc現在擁有該公司35,491股股票,價值99.8萬美元,在此期間又購買了9,791股。高盛股份有限公司在第二季度增持了49.9%的Zentaris製藥股份。高盛股份有限公司在此期間又購買了132,324股,目前持有397,570股該公司股票,價值11,171,000美元。最後,Woodline Partners LP在第二季度將其在Zentalis製藥公司的頭寸增加了344.9%。Woodline Partners LP現在擁有181,272股該公司的股票,價值5094,000美元,在此期間又購買了140,524股。
Zentalis Pharmaceuticals Company Profile
Zentaris製藥公司簡介
(Get Rating)
(獲取評級)
Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; Phase 1/2 clinical trial for the treatment of advanced solid tumors as a monotherapy and in an ongoing Phase 1b clinical trial in combination with chemotherapy in patients with platinum resistant ovarian cancer; and Phase 2 monotherapy trial for a tumor agnostic, predictive biomarker.
Zentalis製藥公司是一家臨牀階段的生物製藥公司,專注於發現和開發用於治療各種癌症的小分子療法。它的主要候選產品包括WEE1的抑制劑ZN-c3,這是一種蛋白質酪氨酸激酶,正處於治療晚期實體腫瘤的第二階段臨牀試驗;作為單一療法治療晚期實體腫瘤的第1/2階段臨牀試驗,以及正在進行的與鉑耐藥卵巢癌患者的聯合化療的1b階段臨牀試驗;以及腫瘤不可知的、可預測的生物標記物的第二階段單一治療試驗。
Featured Articles
專題文章
- Get a free copy of the StockNews.com research report on Zentalis Pharmaceuticals (ZNTL)
- Stock Market: 3 Islands Of Strength In A Sea Of Red
- 3 Banks Worth Considering For Q4
- No One Told These 3 Stocks It's a Down Week
- Is There a Cure for What is Ailing Teladoc Stock?
- MarketBeat: Week in Review 9/12 – 9/16
- 免費獲取StockNews.com關於Zentalis製藥的研究報告(ZNTL)
- 股市:紅海中的三座強國
- 第四季度值得考慮的3家銀行
- 沒有人告訴這三隻股票這是下跌的一週
- 有什麼辦法可以治癒Teladoc股票的問題嗎?
- MarketBeat:回顧一週9/12-9/16
Receive News & Ratings for Zentalis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zentalis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
獲得Zentaris製藥日報的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對Zentalis製藥公司和相關公司的最新新聞和分析師評級的每日簡要摘要。